Meerbusch, Germany – Biologics are more effective at treating adult-onset Still’s disease (AOSD) than are glucocorticoids or conventional disease-modifying antirheumatic drugs (DMARDs), according to a new retrospective study. Half of the patients treated with first-line biologic DMARDs achieved sustained, event-free remission compared with 12% of patients in the conventional therapy...
research News
Waltham, MA – A small study of 15 patients published Thursday in The New England Journal of Medicine provides strong evidence of the therapeutic potential of CD19 CAR-T therapies in autoimmune disorders. The study, conducted in Germany, enrolled patients who had been diagnosed with systemic lupus erythematosus (SLE), idiopathic inflammatory...
Barcelona, Spain – Researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Barcelona Supercomputing Center-Centro Nacional de Supercomputación (BSC-CNS) have discovered new genetic mechanisms related to spinocerebellar ataxia type 37. Their research, published in the journal Human Genetics, employed advanced techniques such as CRISPR/Cas9 gene editing, real-time large DNA...
East Lansing, Michigan – Researchers at Michigan State University may have discovered why visceral pain is so common in people who have experienced inflammation in their guts, including patients with irritable bowel syndrome, or IBS. Working with mouse models, MSU physiologists showed that nervous system cells known as glia can...
BUFFALO, NY – A new research paper was published in Oncotarget’s Volume 14, entitled, “The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.” To evade cell cycle controls, malignant cells rely upon rapid expression of...
BUFFALO, NY- March 4, 2024 – A new research paper was published in Oncotarget’s Volume 15 on February 22, 2024, entitled, “Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas.” Sacituzumab govitecan (SG) is an antibody-drug conjugate composed of an anti-Trop-2-directed...
FOSTER CITY, Calif. — Gilead Sciences, Inc., today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC). EVOKE-01 is evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) vs. docetaxel in patients with metastatic or advanced NSCLC...
Gilteritinib may improve long-term outcomes, compared with salvage chemotherapy, in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML), according to updated data from the ADMIRAL trial published in Blood. [1] The phase 3 ADMIRAL trial (ClinicalTrials.gov Identifier: NCT02997202) enrolled adults with FLT3-mutated AML who were in their first relapse after...
SAN CARLOS, Calif. – Glycomine, Inc., a biotechnology company focused on developing new therapies for orphan diseases, today announced the publication in Molecular Genetics and Metabolism of a key finding from a natural history study of phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare pediatric orphan disease. In this study, the levels...
A group of genetically modified monkeys with glow-in-the-dark feet could help advance research into neurological illnesses such as Parkinson’s and Huntington’s. Genetically modified monkeys in scientific research are not uncommon, however, these are the first family to pass a manufactured genetic trait onto a second generation.The monkeys, which were created...